300 related articles for article (PubMed ID: 23483513)
1. Preservative-free treatment in glaucoma: who, when, and why.
Stalmans I; Sunaric Mégevand G; Cordeiro MF; Hommer A; Rossetti L; Goñi F; Heijl A; Bron A
Eur J Ophthalmol; 2013; 23(4):518-25. PubMed ID: 23483513
[TBL] [Abstract][Full Text] [Related]
2. Fixed-combination intraocular pressure-lowering therapy for glaucoma and ocular hypertension: advantages in clinical practice.
Holló G; Topouzis F; Fechtner RD
Expert Opin Pharmacother; 2014 Aug; 15(12):1737-47. PubMed ID: 24998246
[TBL] [Abstract][Full Text] [Related]
3. IOP-lowering efficacy and tolerability of preservative-free tafluprost 0.0015% among patients with ocular hypertension or glaucoma.
Hommer A; Mohammed Ramez O; Burchert M; Kimmich F
Curr Med Res Opin; 2010 Aug; 26(8):1905-13. PubMed ID: 20553122
[TBL] [Abstract][Full Text] [Related]
4. [Corneal sensitivity in patients treated medically for glaucoma or ocular hypertension].
Van Went C; Alalwani H; Brasnu E; Pham J; Hamard P; Baudouin C; Labbé A
J Fr Ophtalmol; 2011 Dec; 34(10):684-90. PubMed ID: 22093372
[TBL] [Abstract][Full Text] [Related]
5. Preservative-free tafluprost 0.0015% in the treatment of patients with glaucoma and ocular hypertension.
Erb C; Lanzl I; Seidova SF; Kimmich F
Adv Ther; 2011 Jul; 28(7):575-85. PubMed ID: 21725844
[TBL] [Abstract][Full Text] [Related]
6. Ocular Surface Disease in Glaucoma: Effect of Polypharmacy and Preservatives.
Ramli N; Supramaniam G; Samsudin A; Juana A; Zahari M; Choo MM
Optom Vis Sci; 2015 Sep; 92(9):e222-6. PubMed ID: 25730335
[TBL] [Abstract][Full Text] [Related]
7. Preservative-Free Prostaglandin Analogs and Prostaglandin/Timolol Fixed Combinations in the Treatment of Glaucoma: Efficacy, Safety and Potential Advantages.
Holló G; Katsanos A; Boboridis KG; Irkec M; Konstas AGP
Drugs; 2018 Jan; 78(1):39-64. PubMed ID: 29196953
[TBL] [Abstract][Full Text] [Related]
8. An in vivo confocal microscopy analysis of effects of topical antiglaucoma therapy with preservative on corneal innervation and morphology.
Martone G; Frezzotti P; Tosi GM; Traversi C; Mittica V; Malandrini A; Pichierri P; Balestrazzi A; Motolese PA; Motolese I; Motolese E
Am J Ophthalmol; 2009 Apr; 147(4):725-735.e1. PubMed ID: 19181302
[TBL] [Abstract][Full Text] [Related]
9. [The influence of ocular surface diseases in the management of glaucoma].
Van Went C; Brasnu E; Hamard P; Baudouin C; Labbé A
J Fr Ophtalmol; 2011 Apr; 34(4):230-7. PubMed ID: 21439676
[TBL] [Abstract][Full Text] [Related]
10. A comparative study of a preservative-free latanoprost cationic emulsion (Catioprost) and a BAK-preserved latanoprost solution in animal models.
Daull P; Buggage R; Lambert G; Faure MO; Serle J; Wang RF; Garrigue JS
J Ocul Pharmacol Ther; 2012 Oct; 28(5):515-23. PubMed ID: 22671995
[TBL] [Abstract][Full Text] [Related]
11. [Advances in preservative-free glaucoma drops].
Stefan C; Pop A; Cojocaru I
Oftalmologia; 2011; 55(2):3-6. PubMed ID: 21888063
[TBL] [Abstract][Full Text] [Related]
12. Effects of topical low-dose preservative-free hydrocortisone on intraocular pressure in patients affected by ocular surface disease with and without glaucoma.
Filippelli M; dell'Omo R; Gelso A; Rinaldi M; Bartollino S; Napolitano P; Russo A; Campagna G; Costagliola C
Graefes Arch Clin Exp Ophthalmol; 2022 Jan; 260(1):247-253. PubMed ID: 34406502
[TBL] [Abstract][Full Text] [Related]
13. A review of preserved and preservative-free prostaglandin analogues for the treatment of open-angle glaucoma and ocular hypertension.
Hommer A
Drugs Today (Barc); 2010 Jun; 46(6):409-16. PubMed ID: 20571609
[TBL] [Abstract][Full Text] [Related]
14. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication.
Uusitalo H; Chen E; Pfeiffer N; Brignole-Baudouin F; Kaarniranta K; Leino M; Puska P; Palmgren E; Hamacher T; Hofmann G; Petzold G; Richter U; Riedel T; Winter M; Ropo A
Acta Ophthalmol; 2010 May; 88(3):329-36. PubMed ID: 20546237
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of preservative-free eye drops containing a fixed combination of dorzolamide and timolol in glaucoma patients.
Renieri G; Führer K; Scheithe K; Lorenz K; Pfeiffer N; Thieme H
J Ocul Pharmacol Ther; 2010 Dec; 26(6):597-603. PubMed ID: 20977366
[TBL] [Abstract][Full Text] [Related]
16. Tafluprost/Timolol: A Review in Open-Angle Glaucoma or Ocular Hypertension.
Hoy SM
Drugs; 2015 Oct; 75(15):1807-13. PubMed ID: 26431840
[TBL] [Abstract][Full Text] [Related]
17. Ocular Surface Disease in Patients under Topical Treatment for Glaucoma.
Pérez-Bartolomé F; Martínez-de-la-Casa JM; Arriola-Villalobos P; Fernández-Pérez C; Polo V; García-Feijoó J
Eur J Ophthalmol; 2017 Nov; 27(6):694-704. PubMed ID: 28497458
[TBL] [Abstract][Full Text] [Related]
18. Glaucoma therapy and ocular surface disease: current literature and recommendations.
Anwar Z; Wellik SR; Galor A
Curr Opin Ophthalmol; 2013 Mar; 24(2):136-43. PubMed ID: 23542350
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of preservative-free latanoprost eyedrops, compared with BAK-preserved latanoprost in patients with ocular hypertension or glaucoma.
Rouland JF; Traverso CE; Stalmans I; Fekih LE; Delval L; Renault D; Baudouin C;
Br J Ophthalmol; 2013 Feb; 97(2):196-200. PubMed ID: 23203707
[TBL] [Abstract][Full Text] [Related]
20. Topical preservative-free ophthalmic treatments: an unmet clinical need.
Figus M; Agnifili L; Lanzini M; Brescia L; Sartini F; Mastropasqua L; Posarelli C
Expert Opin Drug Deliv; 2021 Jun; 18(6):655-672. PubMed ID: 33280452
[No Abstract] [Full Text] [Related]
[Next] [New Search]
